SORRENTO THERAPEUTICS, INC. Form 8-K (March 18, 2022)

Summary

Current report on Form 8-K for an event dated March 18, 2022, filed by Sorrento Therapeutics, Inc. Under Item 7.01 (Regulation FD Disclosure), the report states that on March 18, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento, posted a corporate presentation on Scilex's website. Representatives of Scilex expect to use the presentation in industry conferences, investor conferences and investor meetings from time to time. The presentation is furnished as Exhibit 99.1, and Henry Ji signed on March 18, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): March 18, 2022

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure .

On March 18, 2022, Scilex
Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc., posted on Scilex’s website at
https://www.scilexholding.com/ a corporate presentation. Representatives of Scilex expect to use the presentation in industry conferences,
investor conferences and investor meetings from time to time. A copy of the presentation is furnished hereto as Exhibit 99.1 to this Current
Report on Form 8-K.

The
information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) , or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit.

99.1 | Scilex Holding Company Corporate Presentation (March 2022).
104 | Cover Page interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: March 18, 2022 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2022-03-18_0001104659-22-035633.htm

Size

24,539 bytes

SHA-256

78d8a917f6740bd94ae1c5eedae3275bbe13715162a0a0cc6d32e5e4ff28192b

Our copy

SEC_SRNE_8-K_filed2022-03-18_0001104659-22-035633.htm

Original

www.sec.gov